The drug, PEGPH20, was designed to treat pancreatic cancer, but failed to extend the lives of patients. As a result, the drugmaker will halt all studies of the drug and instead prioritize its drug delivery technology, Enhanze, which is used by several large drugmakers.
To become profitable, the company will cut 160 jobs. It expects to be profitable by the middle of next year, Halozyme CEO Helen Torley told STAT. Halozyme’s board also authorized the company to repurchase $350 million worth of Halozyme stock over the next three years in an effort to raise the share price.
The company also told STAT it believes revenue from Enhanze will reach $1 billion by 2027. Enhanze turns medicines that have to be given intravenously over hours into shots that patients can receive in minutes. Roche and Bristol-Myers Squibb are using the technology for their cancer drugs, as are several other large drugmakers.
Read the full article here.
More articles on pharmacy:
Amgen exits neuroscience research, cuts 180 US jobs
Walgreens’ exit from health clinic business should serve as a warning to rivals
Top 10 pharmacy stories in October
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
